Aripiprazole Intermediate CAS 129722-34-5 Purity >98.0% (HPLC) High Quality
Shanghai Ruifu Chemical Co., Ltd. is the leading supplier of 7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone (CAS: 129722-34-5) with high quality, intermediate of Aripiprazole (CAS: 129722-12-9).
Purchase intermediates of Aripiprazole, please contact us by e-mail: alvin@ruifuchem.com
| Chemical Name | 7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone |
| Synonyms | 7-(4-Bromobutoxy)-3,4-Dihydroquinolin-2(1H)-one; 7-(4-Bromobutoxy) -1,2,3,4-Tetrahydro-2-Oxoquinoline; 3,4-Dihydro-7-(4-Bromobutoxy)-2(1H)-Quinolinone; Aripiprazole Impurity 3 |
| CAS Number | 129722-34-5 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C13H16BrNO2 |
| Molecular Weight | 298.18 |
| Melting Point | 110.0~114.0℃ |
| Density | 1.383±0.06 g/cm3 |
| COA & MSDS | Available |
| Origin of Product | Shanghai, China |
| Product Categories | Pharmaceutical Intermediates |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Pale Yellow Crystal Powder |
| Purity / Analysis Method | >98.0% (HPLC) |
| Melting Point | 110.0~114.0℃ |
| Loss on Drying | <1.00% |
| Residue on Ignition | <0.50% |
| Heavy Metals (as Pb) | ≤20ppm |
| 1H NMR Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Application | Intermediate of Aripiprazole (CAS: 129722-12-9) |
Package: Fluorinated bottle, aluminium foil bag, 25kg/cardboard drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed. Store in a cool, dry and well-ventilated warehouse away from incompatible substances. Keep away from direct sunlight; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by sea, by FedEx / DHL Express. Provide fast and reliable delivery.
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone (CAS: 129722-34-5) is an intermediate in the synthesis of Aripiprazole (CAS: 129722-12-9). A degradation product in Aripiprazole tablets. Aripiprazole (Abilify). The newest, longactingaripiprazole (an arylpiperazine quinolinone derivative), appears to be partial agonist of D2 receptors (i.e., itstimulates certain D2 receptors while blocking others dependingon their locations in the brain and the concentrationof drug). Bioavailability of Aripiprazole is around 87%, with peak plasma concentration attained at 3 to 5 hours afterdosing. It is metabolized by dehydrogenation, oxidative hydroxylation, and N-dealkylation, largely mediated by hepatic CYPs 3A4 and 2D6. For the treatment of schizophrenia and related psychotic disorders. A selective dopamine D2-receptor antagonist with dopamine autoreceptor agonist activity. Antipsychotic.
